Vitura’s Cortexa Forecasts Over $1M in First MDMA Batch Sales
Cortexa secures over $1 million in MDMA sales as psychedelic supply ramps up
Vitura Health (ASX: VIT) has reported that Cortexa MDMA Supply Commercialisation activities have achieved a material milestone, with first batch sales forecast to exceed $1.0 million. Cortexa, a 50/50 joint venture between Vitura and PharmAla Biotech (CSE: MDMA), has now committed most of its initial GMP batch through supply arrangements with authorised providers across Australia. This follows completion of the world’s largest (and first Australian) GMP batch of MDMA capsules earlier in FY2026, representing commercial validation of Vitura’s diversification strategy beyond medicinal cannabis.
The joint venture secured supply arrangements with authorised providers nationally to support clinical programmes and patient treatment under Australia’s regulated prescribing pathways. Through Cortexa’s market activities during Q3 FY2026, the initial batch has been substantially allocated, contributing to the forecast sales value of over $1.0 million. The achievement positions the joint venture as a market leader in therapeutic MDMA supply during FY2026.
When big ASX news breaks, our subscribers know first
What is GMP MDMA and why does pharmaceutical-grade supply matter?
GMP (Good Manufacturing Practice) refers to the pharmaceutical quality standard required for therapeutic use of medicines in clinical settings. Since 1 July 2023, psychedelics have been available to be prescribed in Australia for the treatment of specific mental health conditions, with Authorised Psychiatrists able to prescribe MDMA under the Therapeutic Goods Administration’s (TGA’s) Authorised Prescriber Scheme.
Cortexa’s products are manufactured to support local clinical research and patient treatments through these authorised channels. The regulatory framework has been established, positioning pharmaceutical-grade supply as the key enabler for therapeutic access. Cortexa’s first-mover positioning in supplying GMP-manufactured MDMA provides strategic advantage in this nascent but growing therapeutic category.
Second production batch underway with new dosage form
PharmAla has initiated production of a second GMP batch featuring a new 20mg dosage form, described as another Australian first. The batch is expected to be available to Cortexa’s customers in Q2 CY2026 (April to June 2026). This capacity expansion is positioned to support current and future demand from authorised providers.
Key production milestones:
- FY2026 – World’s largest (and first Australian) GMP MDMA batch completed
- Q3 FY2026 – Most of initial batch committed with sales forecast exceeding $1.0 million
- Q2 CY2026 – Second batch with 20mg dosage expected to become available
Chief Revenue Officer Ryan Tattle stated: “Cortexa’s significant increase in its supply of MDMA confirms its confidence of the expected sizeable growth in the psychedelics market in Australia.”
Licensing arrangement concludes with ongoing IP access
The previously contracted three-year licence arrangement with joint venture partner PharmAla Biotech, which involved annual licence payments of $250,000 for manufacturing and intellectual property rights, concludes during FY2026. The completion of this arrangement continues to allow ongoing access to the relevant manufacturing processes and associated intellectual property exclusively provided for the Cortexa joint venture structure.
Critically, Cortexa will continue to benefit from PharmAla’s product development activity, with the joint venture retaining right of first refusal on any new innovations developed by PharmAla for the Australian market. This structure eliminates the recurring annual cost from FY2027 onwards while maintaining strategic access to manufacturing IP and future innovations.
| Milestone | Status | Value/Detail | Timing |
|---|---|---|---|
| First GMP batch | Completed | World’s largest & Australia’s first | FY2026 |
| Batch committed | Most committed | >$1.0M forecast | Q3 FY2026 |
| Second batch (20mg) | In production | New dosage form | Q2 CY2026 |
| Licence payments | Concluding | $250K/year saved | End FY2026 |
Broader market tailwinds support growth outlook
Developments in the Australian healthcare system continue to support the emerging psychedelic therapies sector, including reimbursement initiatives from organisations such as Medibank Private and treatment support programmes through the Department of Veterans’ Affairs. These healthcare system developments are positioned to de-risk the sector for commercial supply partners like Cortexa.
The next major ASX story will hit our subscribers first
Strategic value within Vitura’s diversified health portfolio
The operational progress reflects the strength of Cortexa’s commercial strategy within Vitura’s broader health portfolio. Mr Tattle commented on the diversification benefit:
Ryan Tattle, Chief Revenue Officer
“Cortexa provides Vitura with an important diversification of its revenue streams. The Cortexa team at Vitura are to be congratulated on furthering the commercial operations through its supply arrangements.”
Cortexa operates alongside Vitura’s established businesses, including the Canview medicinal cannabis platform serving approximately 4,700 Australian pharmacies, and telehealth assets such as Doctors on Demand. Vitura is fully licensed and equipped through its distribution centres in Melbourne and the Gold Coast to distribute all products under Schedules 2, 3, 4, 8 and 9, providing infrastructure capability to support psychedelic medicines distribution.
Cortexa expects these developments to underpin the joint venture’s planned commercial growth outcomes for FY2026 and beyond, with the second batch production and concluded licensing arrangement positioned to support margin expansion and supply capacity through the remainder of the financial year.
Want the Next Psychedelic Healthcare Breakout in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to receive real-time alerts the moment market-moving announcements hit the ASX.